MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
ATM is a tumor suppressor often mutated in lung adenocarcinoma. In this study, the authors starting from a synthetic lethal screen, demonstrate that tumor cells with mutations in ATM exhibit increased sensitivity to MEK1/2 inhibition through the modulation of the AKT/mTOR pathway.
Guardado en:
Autores principales: | Michal Smida, Ferran Fece de la Cruz, Claudia Kerzendorfer, Iris Z. Uras, Barbara Mair, Abdelghani Mazouzi, Tereza Suchankova, Tomasz Konopka, Amanda M. Katz, Keren Paz, Katalin Nagy-Bojarszky, Markus K. Muellner, Zsuzsanna Bago-Horvath, Eric B. Haura, Joanna I. Loizou, Sebastian M. B. Nijman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d580c8bada764855b9d9cdb7d5d53e6b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A novel, ataxic mouse model of ataxia telangiectasia caused by a clinically relevant nonsense mutation
por: Harvey Perez, et al.
Publicado: (2021) -
Exposure of the cytoplasm to low-dose X-rays modifies ataxia telangiectasia mutated-mediated DNA damage responses
por: Munetoshi Maeda, et al.
Publicado: (2021) -
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
por: Rebeka Sultana, et al.
Publicado: (2013) -
An anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T)
por: A.J. Yeo, et al.
Publicado: (2021) -
ATM Kinase Dead: From Ataxia Telangiectasia Syndrome to Cancer
por: Sabrina Putti, et al.
Publicado: (2021)